FDA approves a second Alzheimer's drug that can modestly slow disease

  • 📰 CTVNews
  • ⏱ Reading Time:
  • 114 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 49%
  • Publisher: 99%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.

The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday, July 2, 2024 for mild or early cases of dementia caused by Alzheimer’s.

Both Kisunla and the Japanese drug, Leqembi, are laboratory-made antibodies, administered by IV, that target one contributor to Alzheimer's — sticky amyloid plaque buildup in the brain. Questions remain about which patients should get the drugs and how long they might benefit. The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22 per cent more slowly in terms of memory and cognitive ability than those who received a dummy infusion.

First, doctors need to confirm that patients with dementia have the brain plaque targeted by the new drugs. Then they need to find a drug infusion center where patients can receive therapy. Meanwhile, nurses and other staff must be trained to perform repeated scans to check for brain swelling or bleeding.

Democratic Rep. Lloyd Doggett of Texas on Tuesday became the first sitting Democratic member of Congress to call on U.S. President Joe Biden to withdraw from the presidential race, a huge moment for the Democratic Party as Doggett says publicly what many elected officials had been speculating about privately.Thousands of people at a religious gathering in India rushed to leave a makeshift tent, setting off a stampede Tuesday that killed more than 100 and left scores injured, officials said.

They set off around the world on a motorcycle and 'fell off many times.' Now they’re in the record books Free agent Klay Thompson has reportedly agreed to a three-year, US$50 million deal with the Dallas Mavericks after confirming his departure from the Golden State Warriors.Marketa Vondrousova is the first defending women's Wimbledon champ out in the first round since 1994

TTC lacked proper measures to prevent 2021 cyberattack despite internal warning years earlier: reports A fire that broke out in an industrial area east of Edmonton on Canada Day has destroyed an unused cooling tower.The Edmonton Oilers play their first four games of the season at Rogers Place, starting with the Winnipeg Jets on Wednesday, Oct. 9.A boil-water advisory warning residents of the possibility of unsafe drinking water within the Halifax Regional Municipality remains in place Tuesday.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 1. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA Staff Proposes Narrow Approval for Lilly’s Alzheimer’s DrugUS drug regulatory staffers are considering a more targeted approval for Eli Lilly & Co.’s experimental Alzheimer’s disease treatment than the company wants, potentially limiting the market for a would-be blockbuster.
Source: BNNBloomberg - 🏆 83. / 50 Read more »

Lilly Alzheimer’s Drug Seen Effective by FDA Advisory PanelEli Lilly & Co.’s treatment for Alzheimer’s disease works in at least some patients, according to a US advisory panel.
Source: BNNBloomberg - 🏆 83. / 50 Read more »

Alzheimer's drug that can slow disease gets backing from FDA advisersWASHINGTON (AP) — A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the...
Source: YahooFinanceCA - 🏆 47. / 63 Read more »

FDA panel votes unanimously for Eli Lilly's Alzheimer's treatmentAn FDA panel voted unanimously to support Eli Lilly's Alzheimer's drug for use in adults 60-85 years old.
Source: YahooFinanceCA - 🏆 47. / 63 Read more »

Alzheimer's drug that can slow disease gets backing from FDA advisersA closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease.
Source: CTVNews - 🏆 1. / 99 Read more »